 |
PDBsum entry 6o2c
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immune system
|
PDB id
|
|
|
|
6o2c
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
225 a.a.
|
|
|
|
|
|
|
|
|
|
|
215 a.a.
|
|
|
|
|
|
|
|
|
|
|
121 a.a.
|
|
|
|
|
|
|
|
|
|
|
11 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Immune system
|
|
|
Title:
|
|
Crystal structure of 4493 fab in complex with circumsporozoite protein nanp3 and anti-kappa vhh domain
|
|
Structure:
|
|
4493 fab heavy chain. Chain: a. Engineered: yes. 4493 kappa light chain. Chain: b. Engineered: yes. Anti-kappa vhh domain. Chain: k. Engineered: yes.
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: homo sapiens. Expression_system_taxid: 9606. Lama glama. Llama. Organism_taxid: 9844. Expressed in: escherichia coli.
|
|
Resolution:
|
|
|
2.02Å
|
R-factor:
|
0.163
|
R-free:
|
0.195
|
|
|
Authors:
|
|
S.W.Scally,A.Bosch,K.Prieto,R.Murugan,H.Wardemann,J.P.Julien
|
|
Key ref:
|
|
R.Murugan
et al.
(2020).
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.
Nat Med,
26,
1135-1145.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
22-Feb-19
|
Release date:
|
01-Jul-20
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Nat Med
26:1135-1145
(2020)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.
|
|
R.Murugan,
S.W.Scally,
G.Costa,
G.Mustafa,
E.Thai,
T.Decker,
A.Bosch,
K.Prieto,
E.A.Levashina,
J.P.Julien,
H.Wardemann.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The circumsporozoite protein of the human malaria parasite Plasmodium falciparum
(PfCSP) is the main target of antibodies that prevent the infection and disease,
as shown in animal models. However, the limited efficacy of the PfCSP-based
vaccine RTS,S calls for a better understanding of the mechanisms driving the
development of the most potent human PfCSP antibodies and identification of
their target epitopes. By characterizing 200 human monoclonal PfCSP antibodies
induced by sporozoite immunization, we establish that the most potent antibodies
bind around a conserved (N/D)PNANPN(V/A) core. High antibody affinity to the
core correlates with protection from parasitemia in mice and evolves around the
recognition of NANP motifs. The data suggest that the rational design of a
next-generation PfCSP vaccine that elicits high-affinity antibody responses
against the core epitope will promote the induction of protective humoral immune
responses.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
| | |
Links
